Our mission is to transform the clinical management of patients with cancer by developing and delivering innovative molecular imaging technologies to address unmet clinical needs and reliably inform diagnosis and treatment decisions.
Our team is made up of industry leaders and experts in the field of radiopharmaceuticals development and commercialisation.
Blue Earth Diagnostics is funded by Syncona LLP, a subsidiary of the Wellcome Trust, the second largest philanthropic, not-for-profit healthcare foundation in the world.
Find out how this technique works
Find out about prostate cancer
Cellular mechanisms for Amino Acide transport
Our research focus
Who we are
Who we work with
See how you can join the team
Where we are going to be
– Axumin Recently FDA-approved to Detect Recurrent Prostate Cancer – BURLINGTON, Mass. and OXFORD, England, September 8, 2016 – Blue Earth Diagnostics, a molecular imaging diagnostics company, today...
Read More ›– Recently FDA-Approved F 18 PET Imaging Agent for Patients with Suspected Biochemically Recurrent Prostate Cancer Now Also in Use at Additional Medical Centers – BURLINGTON, Mass. and OXFORD,...
Read More ›Blue Earth Diagnostics Announces AxuminTM (Fluciclovine F 18) Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting – Axumin Recently FDA-approved to Detect Recurrent Prostate...
Read More ›Blue Earth Diagnostics and Siemens’ PETNET Solutions Announce Commercial Availability of AxuminTM (Fluciclovine F 18) Injection for PET Imaging of Recurrent Prostate Cancer BURLINGTON, Mass., OXFORD, England & Malvern,...
Read More ›